Wealth Enhancement Advisory Services’s Gain Therapeutics GANX Stock Holding History
Bought
Maintained
Sold
Other funds holding GANX
PCM
Wealth Enhancement Advisory Services's GANX Position: Q3 2026 in Review
Wealth Enhancement Advisory Services held its Gain Therapeutics (GANX) position steady in Q3 2026 at 17,056 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4095.
Wealth Enhancement Advisory Services first reported a position in GANX in Q3 2025 and has held it in 5 quarters since. The position peaked at $39.7K in Q4 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q3 2026.
- Wealth Enhancement Advisory Services held 17,056 shares of Gain Therapeutics worth $27.5K as of Q3 2026.
- Wealth Enhancement Advisory Services left its Gain Therapeutics share count unchanged in Q3 2026.
- Gain Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4095 holding.
- Wealth Enhancement Advisory Services first reported a position in Gain Therapeutics in Q3 2025 and has held it in 5 quarters since.
- Wealth Enhancement Advisory Services's Gain Therapeutics position peaked at $39.7K in Q4 2025.
- 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2026.
Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.